Comprehensive Precision Medicine holistically integrates essential and interconnecting disciplines that contribute to the make-up of Precision Medicine as we know it today. Encompassing almost 90 contributions from eminent scholars and professionals, the book's contents are organized across 3 volumes and 7 major subject areas, each representing a key pillar driving the evolution and progression of healthcare delivery. Precision medicine approaches will transform the training and practice of all aspects of professional healthcare delivery, including medicine, nursing, pharmacy, psychology, rehabilitation, and social work. This will be a fundamental reference resource for students, post-graduate trainees, researchers, scientists and clinicians interested in precision medicine.
Additionally, this resource will be of interest to regulators, policy makers, and public health practitioners across the globe.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Editor Biographies - p. iii 7. Preface - p. iii 8. Artificial Intelligence, Biomedical Informatics and Computational Biology in Precision Medicine - p. iii 9. 1.01. Enhancing Precision Medicine and Wellness with Computing and AI across Clinical, Imaging, Environmental, Multi-Omics, Wearable Sensors, and Socio-Cognitive Data - p. iii 10. 1.02. Artificial Intelligence and Bioinformatics Applications in Precision Medicine and Future Implications - p. iii 11. 1.03. Ontology anchored decision support tools: A focus on pharmacogenomics - p. iii 12. 1.04. Precision clinical genomics and single subject studies of multi-omics data - p. iii 13. 1.05. Computational precision therapeutics and drug repositioning - p. iii 14. 1.06. Transformer-based modeling to study repetitive sequences of the human genome - p. iii 15. 1.07. A Blueprint for Next Generation of Clinical Trials in Precision Psychiatry - p. iii 16. 1.08. Neural networks in medical imaging - p. iii 17. 1.09. Data continuity and linkage in the healthcare ecosystem - p. iii 18. 1.10. AI-powered drug repurposing for developing COVID-19 treatments - p. iii 19. Clinical Applications in Precision Medicine - p. iii 20. 2.01. The role of family history in precision medicine - p. iii 21. 2.02. New approaches to genetic counseling - p. iii 22. 2.03. The expansion of genomic precision medicine to prenatal care - p. iii 23. 2.04. Genomics screening of neonates - p. iii 24. 2.05. Genomic approaches to rare disorder diagnosis - p. iii 25. 2.06. Approach to adult-onset mendelian disorders - p. iii 26. 2.07. Targeted Therapeutics for Rare Disorders - p. iii 27. 2.08. Precision medicine-based cancer care - p. iii 28. 2.09. Education of health providers on precision medicine - p. iii 29. 2.10. A primer to implementation science and potential applications to precision medicine - p. iii 30. 2.11. Protection of privacy in genomic medicine - p. iii 31. 2.12. Population genomic screening - p. iii 32. Behavioral, Environmental and Social Determinants of Health - p. iii 33. 3.01. Health care systems, social adversity, and precision medicine - p. iii 34. 3.02. The environment, public health and personalized medicine: Where do we go from here? - p. iii 35. Social determinants of health: How social and environmental factors affect human health - p. iii 36. 3.04. Incorporation of social determinants of health into health care practice: A strategy to address health disparities - p. iii 37. 3.05. Acquired susceptivity phenotype: A target for precision - p. iii 38. 3.06. Impact of social determinants of health on DNA methylation - p. iii 39. 3.07. Environment-induced epigenetic modifications as therapeutic targets for prevention and treatment - p. iii 40. 3.08. Epigenetic regulation: Histone modifying enzymes as targets for novel therapeutics - p. iii 41. 3.09. Effect of environmental toxicants on the epigenome and current applications - p. iii 42. 3.10. Genetic and Epigenetic Dysregulation in Environmental Disease - p. iii 43. 3.11. Sociobehavioral-induced epigenetic variation and psychiatric diseases - p. iii 44. 3.12. Economic inequality: The principal social determinant of health responsible for disparity in life-expectancy - p. iii 45. Digital Health in Precision Medicine - p. iii 46. 4.01. Synergistic Approaches of Cross-Fertilization and Feedback Together Driving and Advancing Health for All - p. iii 47. 4.02. “Social media, wearables, telemedicine and digital health,”—A Gen Y and Z perspective - p. iii 48. 4.03. Health information - Evolving complexities of data privacy, security, and digital health in the Era of precision medicine - p. iii 49. 4.04. Interfacing and integrating digital technologies in the electronic health record - p. iii 50. 4.05. Cell phone-based health systems for remote access—Evolution, capabilities, applications and impact for precision medicine and beyond - p. iii 51. 4.06. Digital Cardiovascular Medicine – Patient, Doctor, Devices - p. iii 52. 4.07. Digital technologies and pulmonary medicine - p. iii 53. 4.08. Digital neurology: Personalizing diagnosis and treatment - p. iii 54. 4.09. Digital health and renal disease - p. iii 55. 4.10. Digital twin - p. iii 56. Omics Technologies in Precision Medicine - p. iii 57. 5.01. The power of whole genomic sequencing in biomedical research and clinical applications - p. iii 58. 5.02. Exome and targeted sequencing in clinical oncology- Diffuse large B-cell lymphoma as a model - p. iii 59. 5.03. Evolution of genome wide approaches to unveil transcriptional networks - p. iii 60. 5.04. The application of RNA sequencing in precision cancer medicine - p. iii 61. 5.05. Single-Cell mRNA Sequencing in Precision Medicine: Promise and Challenges - p. iii 62. 5.06. Single B-cell sequencing in monoclonal antibody discovery - p. iii 63. 5.07. Innovative strategies to study epigenetic regulation and advance precision medicine - p. iii 64. 5.08. Profiling cell phenotypes and functional states using mass cytometry - p. iii 65. 5.09. Liquid biopsy based on circulating tumor DNA for lung cancer: A step toward prevention - p. iii 66. 5.10. Cancer patient stratification based on patterns of immune infiltration - p. iii 67. 5.11. The microbiome and cardiovascular disease: Implications in Precision Medicine - p. iii 68. Commercial, Regulatory, Ethical and Legal Considerations in Precision Medicine - p. iii 69. 6.01. Academic entrepreneurship in academic health systems - p. iii 70. 6.02. Alternative evidence in drug development and regulatory science - p. iii 71. 6.03. Proprietary strategies in precision medicine - p. iii 72. 6.04. Multianalyte tests in clinical care - p. iii 73. 6.05. Companion and complementary diagnostics as tools of precision medicine - p. iii 74. 6.06. Precision medicine and drug safety - p. iii 75. 6.07. Chimeric cohorts and consortia can power and scale precision medicine - p. iii 76. 6.08. Dynamic treatment regimens and biomarker-driven strategies: Bridging the two worlds - p. iii 77. 6.09. Pragmatic solutions for optimizing oncology drug development trials - p. iii 78. 6.10. Nanotechnology in vaccines and personalized medicine - p. iii 79. 6.11. Cell therapy as precision medicine: Clinical, regulatory, and commercial lessons learned from advances in the islet and CAR-T fields - p. iii 80. 6.12. Precision medicine and the ethics of electronic health records and genomics - p. iii 81. Precision Prevention - p. iii 82. 7.01. The role of patient and community engagement and education in advancing precision medicine - p. iii 83. 7.02. Bringing precision medicine to patients with telehealth - p. iii 84. 7.03. Trends and implementation of preemptive pharmacogenomic testing - p. iii 85. 7.04. Experimental precision medicine: Mouse models to test precision medicine - p. iii 86. 7.05. The Role of Organ-on-a-Chip Technology in Advancing Precision Medicine - p. iii 87. 7.06. Novel Biomarkers of Cardiovascular Disease - p. iii 88. 7.07. Pocket cardiology - p. iii 89. 7.08. A computerized scoring system to improve assessment of heparin-induced thrombocytopenia risk - p. iii 90. 7.09. Precision medicine in diabetes - current trends and future directions. Is the future now? - p. iii 91. 7.10. Liquid biopsy in cancer diagnosis, therapy and prognosis - p. iii 92. 7.11. In pursuit of precision medicine for brain injury and neurotoxicity and improved protection of human health - p. iii 93. 7.12. Development of early biomarkers of Alzheimer's disease: A precision medicine perspective - p. iii 94. 7.13. The role of brain noradrenaline in Alzheimer's disease: Implications for a precision medicine-oriented approach - p. iii 95. 7.14. Personalized nutrition - p. iii 96. Index - p. iii 97. Authors - p. iii
Comprehensive Precision Medicine holistically integrates essential and interconnecting disciplines that contribute to the make-up of Precision Medicine as we know it today. Encompassing almost 90 contributions from eminent scholars and professionals, the book's contents are organized across 3 volumes and 7 major subject areas, each representing a key pillar driving the evolution and progression of healthcare delivery. Precision medicine approaches will transform the training and practice of all aspects of professional healthcare delivery, including medicine, nursing, pharmacy, psychology, rehabilitation, and social work. This will be a fundamental reference resource for students, post-graduate trainees, researchers, scientists and clinicians interested in precision medicine.
Additionally, this resource will be of interest to regulators, policy makers, and public health practitioners across the globe.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Editor Biographies - p. iii 7. Preface - p. iii 8. Artificial Intelligence, Biomedical Informatics and Computational Biology in Precision Medicine - p. iii 9. 1.01. Enhancing Precision Medicine and Wellness with Computing and AI across Clinical, Imaging, Environmental, Multi-Omics, Wearable Sensors, and Socio-Cognitive Data - p. iii 10. 1.02. Artificial Intelligence and Bioinformatics Applications in Precision Medicine and Future Implications - p. iii 11. 1.03. Ontology anchored decision support tools: A focus on pharmacogenomics - p. iii 12. 1.04. Precision clinical genomics and single subject studies of multi-omics data - p. iii 13. 1.05. Computational precision therapeutics and drug repositioning - p. iii 14. 1.06. Transformer-based modeling to study repetitive sequences of the human genome - p. iii 15. 1.07. A Blueprint for Next Generation of Clinical Trials in Precision Psychiatry - p. iii 16. 1.08. Neural networks in medical imaging - p. iii 17. 1.09. Data continuity and linkage in the healthcare ecosystem - p. iii 18. 1.10. AI-powered drug repurposing for developing COVID-19 treatments - p. iii 19. Clinical Applications in Precision Medicine - p. iii 20. 2.01. The role of family history in precision medicine - p. iii 21. 2.02. New approaches to genetic counseling - p. iii 22. 2.03. The expansion of genomic precision medicine to prenatal care - p. iii 23. 2.04. Genomics screening of neonates - p. iii 24. 2.05. Genomic approaches to rare disorder diagnosis - p. iii 25. 2.06. Approach to adult-onset mendelian disorders - p. iii 26. 2.07. Targeted Therapeutics for Rare Disorders - p. iii 27. 2.08. Precision medicine-based cancer care - p. iii 28. 2.09. Education of health providers on precision medicine - p. iii 29. 2.10. A primer to implementation science and potential applications to precision medicine - p. iii 30. 2.11. Protection of privacy in genomic medicine - p. iii 31. 2.12. Population genomic screening - p. iii 32. Behavioral, Environmental and Social Determinants of Health - p. iii 33. 3.01. Health care systems, social adversity, and precision medicine - p. iii 34. 3.02. The environment, public health and personalized medicine: Where do we go from here? - p. iii 35. Social determinants of health: How social and environmental factors affect human health - p. iii 36. 3.04. Incorporation of social determinants of health into health care practice: A strategy to address health disparities - p. iii 37. 3.05. Acquired susceptivity phenotype: A target for precision - p. iii 38. 3.06. Impact of social determinants of health on DNA methylation - p. iii 39. 3.07. Environment-induced epigenetic modifications as therapeutic targets for prevention and treatment - p. iii 40. 3.08. Epigenetic regulation: Histone modifying enzymes as targets for novel therapeutics - p. iii 41. 3.09. Effect of environmental toxicants on the epigenome and current applications - p. iii 42. 3.10. Genetic and Epigenetic Dysregulation in Environmental Disease - p. iii 43. 3.11. Sociobehavioral-induced epigenetic variation and psychiatric diseases - p. iii 44. 3.12. Economic inequality: The principal social determinant of health responsible for disparity in life-expectancy - p. iii 45. Digital Health in Precision Medicine - p. iii 46. 4.01. Synergistic Approaches of Cross-Fertilization and Feedback Together Driving and Advancing Health for All - p. iii 47. 4.02. “Social media, wearables, telemedicine and digital health,”—A Gen Y and Z perspective - p. iii 48. 4.03. Health information - Evolving complexities of data privacy, security, and digital health in the Era of precision medicine - p. iii 49. 4.04. Interfacing and integrating digital technologies in the electronic health record - p. iii 50. 4.05. Cell phone-based health systems for remote access—Evolution, capabilities, applications and impact for precision medicine and beyond - p. iii 51. 4.06. Digital Cardiovascular Medicine – Patient, Doctor, Devices - p. iii 52. 4.07. Digital technologies and pulmonary medicine - p. iii 53. 4.08. Digital neurology: Personalizing diagnosis and treatment - p. iii 54. 4.09. Digital health and renal disease - p. iii 55. 4.10. Digital twin - p. iii 56. Omics Technologies in Precision Medicine - p. iii 57. 5.01. The power of whole genomic sequencing in biomedical research and clinical applications - p. iii 58. 5.02. Exome and targeted sequencing in clinical oncology- Diffuse large B-cell lymphoma as a model - p. iii 59. 5.03. Evolution of genome wide approaches to unveil transcriptional networks - p. iii 60. 5.04. The application of RNA sequencing in precision cancer medicine - p. iii 61. 5.05. Single-Cell mRNA Sequencing in Precision Medicine: Promise and Challenges - p. iii 62. 5.06. Single B-cell sequencing in monoclonal antibody discovery - p. iii 63. 5.07. Innovative strategies to study epigenetic regulation and advance precision medicine - p. iii 64. 5.08. Profiling cell phenotypes and functional states using mass cytometry - p. iii 65. 5.09. Liquid biopsy based on circulating tumor DNA for lung cancer: A step toward prevention - p. iii 66. 5.10. Cancer patient stratification based on patterns of immune infiltration - p. iii 67. 5.11. The microbiome and cardiovascular disease: Implications in Precision Medicine - p. iii 68. Commercial, Regulatory, Ethical and Legal Considerations in Precision Medicine - p. iii 69. 6.01. Academic entrepreneurship in academic health systems - p. iii 70. 6.02. Alternative evidence in drug development and regulatory science - p. iii 71. 6.03. Proprietary strategies in precision medicine - p. iii 72. 6.04. Multianalyte tests in clinical care - p. iii 73. 6.05. Companion and complementary diagnostics as tools of precision medicine - p. iii 74. 6.06. Precision medicine and drug safety - p. iii 75. 6.07. Chimeric cohorts and consortia can power and scale precision medicine - p. iii 76. 6.08. Dynamic treatment regimens and biomarker-driven strategies: Bridging the two worlds - p. iii 77. 6.09. Pragmatic solutions for optimizing oncology drug development trials - p. iii 78. 6.10. Nanotechnology in vaccines and personalized medicine - p. iii 79. 6.11. Cell therapy as precision medicine: Clinical, regulatory, and commercial lessons learned from advances in the islet and CAR-T fields - p. iii 80. 6.12. Precision medicine and the ethics of electronic health records and genomics - p. iii 81. Precision Prevention - p. iii 82. 7.01. The role of patient and community engagement and education in advancing precision medicine - p. iii 83. 7.02. Bringing precision medicine to patients with telehealth - p. iii 84. 7.03. Trends and implementation of preemptive pharmacogenomic testing - p. iii 85. 7.04. Experimental precision medicine: Mouse models to test precision medicine - p. iii 86. 7.05. The Role of Organ-on-a-Chip Technology in Advancing Precision Medicine - p. iii 87. 7.06. Novel Biomarkers of Cardiovascular Disease - p. iii 88. 7.07. Pocket cardiology - p. iii 89. 7.08. A computerized scoring system to improve assessment of heparin-induced thrombocytopenia risk - p. iii 90. 7.09. Precision medicine in diabetes - current trends and future directions. Is the future now? - p. iii 91. 7.10. Liquid biopsy in cancer diagnosis, therapy and prognosis - p. iii 92. 7.11. In pursuit of precision medicine for brain injury and neurotoxicity and improved protection of human health - p. iii 93. 7.12. Development of early biomarkers of Alzheimer's disease: A precision medicine perspective - p. iii 94. 7.13. The role of brain noradrenaline in Alzheimer's disease: Implications for a precision medicine-oriented approach - p. iii 95. 7.14. Personalized nutrition - p. iii 96. Index - p. iii 97. Authors - p. iii
